Clostridium difficile – From Colonization to Infection

Clostridium difficile is the most frequent cause of nosocomial antibiotic-associated diarrhea. The incidence of C. difficile infection (CDI) has been rising worldwide with subsequent increases in morbidity, mortality, and health care costs. Asymptomatic colonization with C. difficile is common and a...

Full description

Bibliographic Details
Main Authors: Holger Schäffler, Anne Breitrück
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-04-01
Series:Frontiers in Microbiology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fmicb.2018.00646/full
_version_ 1831754493934436352
author Holger Schäffler
Anne Breitrück
Anne Breitrück
author_facet Holger Schäffler
Anne Breitrück
Anne Breitrück
author_sort Holger Schäffler
collection DOAJ
description Clostridium difficile is the most frequent cause of nosocomial antibiotic-associated diarrhea. The incidence of C. difficile infection (CDI) has been rising worldwide with subsequent increases in morbidity, mortality, and health care costs. Asymptomatic colonization with C. difficile is common and a high prevalence has been found in specific cohorts, e.g., hospitalized patients, adults in nursing homes and in infants. However, the risk of infection with C. difficile differs significantly between these cohorts. While CDI is a clear indication for therapy, colonization with C. difficile is not believed to be a direct precursor for CDI and therefore does not require treatment. Antibiotic therapy causes alterations of the intestinal microbial composition, enabling C. difficile colonization and consecutive toxin production leading to disruption of the colonic epithelial cells. Clinical symptoms of CDI range from mild diarrhea to potentially life-threatening conditions like pseudomembranous colitis or toxic megacolon. While antibiotics are still the treatment of choice for CDI, new therapies have emerged in recent years such as antibodies against C. difficile toxin B and fecal microbial transfer (FMT). This specific therapy for CDI underscores the role of the indigenous bacterial composition in the prevention of the disease in healthy individuals and its role in the pathogenesis after alteration by antibiotic treatment. In addition to the pathogenesis of CDI, this review focuses on the colonization of C. difficile in the human gut and factors promoting CDI.
first_indexed 2024-12-21T23:38:37Z
format Article
id doaj.art-a3e19240488849fcbad6c8145f5e55c1
institution Directory Open Access Journal
issn 1664-302X
language English
last_indexed 2024-12-21T23:38:37Z
publishDate 2018-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Microbiology
spelling doaj.art-a3e19240488849fcbad6c8145f5e55c12022-12-21T18:46:17ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2018-04-01910.3389/fmicb.2018.00646332266Clostridium difficile – From Colonization to InfectionHolger Schäffler0Anne Breitrück1Anne Breitrück2Division of Gastroenterology, Department of Medicine II, University of Rostock, Rostock, GermanyExtracorporeal Immunomodulation Unit, Fraunhofer Institute for Cell Therapy and Immunology, Rostock, GermanyInstitute of Medical Microbiology, Virology and Hygiene, University of Rostock, Rostock, GermanyClostridium difficile is the most frequent cause of nosocomial antibiotic-associated diarrhea. The incidence of C. difficile infection (CDI) has been rising worldwide with subsequent increases in morbidity, mortality, and health care costs. Asymptomatic colonization with C. difficile is common and a high prevalence has been found in specific cohorts, e.g., hospitalized patients, adults in nursing homes and in infants. However, the risk of infection with C. difficile differs significantly between these cohorts. While CDI is a clear indication for therapy, colonization with C. difficile is not believed to be a direct precursor for CDI and therefore does not require treatment. Antibiotic therapy causes alterations of the intestinal microbial composition, enabling C. difficile colonization and consecutive toxin production leading to disruption of the colonic epithelial cells. Clinical symptoms of CDI range from mild diarrhea to potentially life-threatening conditions like pseudomembranous colitis or toxic megacolon. While antibiotics are still the treatment of choice for CDI, new therapies have emerged in recent years such as antibodies against C. difficile toxin B and fecal microbial transfer (FMT). This specific therapy for CDI underscores the role of the indigenous bacterial composition in the prevention of the disease in healthy individuals and its role in the pathogenesis after alteration by antibiotic treatment. In addition to the pathogenesis of CDI, this review focuses on the colonization of C. difficile in the human gut and factors promoting CDI.http://journal.frontiersin.org/article/10.3389/fmicb.2018.00646/fullClostridium difficilemicrobiotaClostridium difficile infectionCDIasymptomatic colonization
spellingShingle Holger Schäffler
Anne Breitrück
Anne Breitrück
Clostridium difficile – From Colonization to Infection
Frontiers in Microbiology
Clostridium difficile
microbiota
Clostridium difficile infection
CDI
asymptomatic colonization
title Clostridium difficile – From Colonization to Infection
title_full Clostridium difficile – From Colonization to Infection
title_fullStr Clostridium difficile – From Colonization to Infection
title_full_unstemmed Clostridium difficile – From Colonization to Infection
title_short Clostridium difficile – From Colonization to Infection
title_sort clostridium difficile from colonization to infection
topic Clostridium difficile
microbiota
Clostridium difficile infection
CDI
asymptomatic colonization
url http://journal.frontiersin.org/article/10.3389/fmicb.2018.00646/full
work_keys_str_mv AT holgerschaffler clostridiumdifficilefromcolonizationtoinfection
AT annebreitruck clostridiumdifficilefromcolonizationtoinfection
AT annebreitruck clostridiumdifficilefromcolonizationtoinfection